Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael S. Seaman, Ph.D.

Co-Author

This page shows the publications co-authored by Michael Seaman and Bruce Walker.
Connection Strength

0.802
  1. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009 Sep 15; 200(6):984-90.
    View in: PubMed
    Score: 0.108
  2. Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Netw Open. 2020 12 01; 3(12):e2030455.
    View in: PubMed
    Score: 0.059
  3. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020 12 03; 383(23):2291-2293.
    View in: PubMed
    Score: 0.059
  4. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight. 2018 03 08; 3(5).
    View in: PubMed
    Score: 0.049
  5. Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. Clin Infect Dis. 2017 04 15; 64(8):1098-1104.
    View in: PubMed
    Score: 0.046
  6. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci Transl Med. 2017 01 18; 9(373).
    View in: PubMed
    Score: 0.045
  7. Increased frequencies of CD8+CD57+ T cells are associated with antibody neutralization breadth against HIV in viraemic controllers. J Int AIDS Soc. 2016; 19(1):21136.
    View in: PubMed
    Score: 0.045
  8. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016 07 28; 535(7613):556-60.
    View in: PubMed
    Score: 0.043
  9. Corrigendum: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2016 07 28; 535(7613):580.
    View in: PubMed
    Score: 0.043
  10. HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell Responses. J Virol. 2015 Dec 09; 90(5):2208-20.
    View in: PubMed
    Score: 0.042
  11. A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathog. 2015 Oct; 11(10):e1005238.
    View in: PubMed
    Score: 0.041
  12. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015 06 25; 522(7557):487-91.
    View in: PubMed
    Score: 0.040
  13. An Inflammatory Profile that Predicts the Development of Neutralizing Antibody Breadth. AIDS Res Hum Retroviruses. 2014 Oct; 30 Suppl 1:A35-6.
    View in: PubMed
    Score: 0.038
  14. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med. 2012 Jul 30; 209(8):1469-79.
    View in: PubMed
    Score: 0.033
  15. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011 Sep 16; 333(6049):1633-7.
    View in: PubMed
    Score: 0.031
  16. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010 Sep 30; 467(7315):591-5.
    View in: PubMed
    Score: 0.029
  17. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009 Apr 02; 458(7238):636-40.
    View in: PubMed
    Score: 0.026
  18. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods. 2009 Apr 15; 343(2):65-7.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.